Skip to content

H01 — Ward-Derived Dual-Cassette Coexistence

Claim

An A. oryzae solid-state configuration can co-express active human lactoferrin and an exact UOX configuration that has already passed its single-payload gates, without a material loss of either payload's measured function or an unacceptable change in host viability, peroxide handling, or specified native-metabolite controls.

This is a narrow cassette-coexistence hypothesis. It does not establish a therapeutic dose, oral efficacy, regulatory status, product architecture, or superiority of one UOX sequence, topology, or host.

Current evidence state

  • Ward 1995 supports recombinant human-lactoferrin expression using a glucoamylase–KEX2 architecture in submerged A. awamori culture. In Vitro; adjacent host and process.
  • Ward 1992 supports recombinant human-lactoferrin expression in A. oryzae. In Vitro; single payload.
  • Huynh 2020, Wakai 2019, and Senoo 2024 support heterologous-protein or multi-enzyme expression capabilities in A. oryzae. None tests the exact H01 dual-payload configuration in solid-state rice culture. In Vitro; adjacent configurations.
  • The literature and patent searches refine construct design but are not biological killshots. No H01 survival event has been recorded.

Parent-organism use history does not transfer to an engineered strain or recombinant payload. Construct, process, containment, exposure, and intended use require configuration-specific review.

Assumptions

  1. A Ward-derived lactoferrin cassette remains active in the selected A. oryzae host and solid-state process.
  2. The independently advanced UOX configuration retains activity in that process.
  3. Co-expression does not create a shared secretion, folding, proteolysis, redox, or metabolic bottleneck that materially degrades either arm.
  4. The assays distinguish active payload from expression alone and include matched inactive-payload and host controls.
  5. The exact advanced UOX configuration—not a preselected A. flavus or C. utilis sequence—is used. Those source families remain unranked until a matched configuration screen supplies comparable evidence.

Required sequence

  1. Build and characterize exact single-payload configurations. Validation §§1.1, 1.2, and 1.5, or an exact external configuration, must establish identity, localization, active UOX, active lactoferrin where relevant, host viability, and assay variance.
  2. Advance the exact UOX configuration through §1.33. COMP-044 establishes only that the legacy unconditional flat-dose classification is not robust to the tested substrate-occupancy and finite-window diagnostics. It does not identify the true physiological regime or select a sequence, host, or topology.
  3. Reproduce UOX in the intended solid-state process. The UOX-only control must retain configuration-level product formation before the dual construct is tested.
  4. Test dual-cassette coexistence. Compare parental host, inactive controls, lactoferrin-only, UOX-only, and dual configurations from qualified batches.
  5. Clear §1.36 before animals. A coexistence result cannot bypass the configuration-specific antioxidant-loss/peroxide safety gate.

Biological killshot

The first H01 killshot is the matched single-versus-dual configuration experiment in validation §1.9.

Measure:

  • UOX product formation under the §1.33 reaction conditions;
  • active lactoferrin and its prespecified functional assay;
  • sequence and cassette state;
  • localization and relevant proteolysis;
  • extracellular peroxide, host viability, and growth;
  • specified native-metabolite controls only where they remain part of the frozen claim.

Before the result-bearing run, use pilot precision and qualified single-payload batches to freeze equivalence, loss, safety, and ambiguity margins. Do not infer clinical sufficiency from an in-vitro pass.

Decision rules

  • Alive: the dual configuration meets the prespecified equivalence and safety margins for both active payloads in independent replication.
  • Killed: both single-payload configurations pass, but the dual configuration crosses a prespecified loss or safety boundary after the allowed architecture iteration.
  • Pending / ambiguous: material identity, assay precision, or single-payload qualification is insufficient, or the result lies between the frozen margins.

A killed coexistence claim does not kill either payload, another host, or the Open Enzyme mission. It redirects the track to separate configurations or closes the multi-payload architecture if no justified alternative remains.

Status

Pending; survival count 0. Design and literature work are complete enough to define the experiment, but no completed biological coexistence test has crossed an H01 decision threshold.

Cross-references